TC Biopharm (NASDAQ:TCBP) Stock Price Down 55.8% – Should You Sell?

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) traded down 55.8% during trading on Thursday . The stock traded as low as $0.50 and last traded at $0.68. 5,325,030 shares were traded during mid-day trading, an increase of 4,130% from the average session volume of 125,889 shares. The stock had previously closed at $1.54.

Analysts Set New Price Targets

Separately, HC Wainwright dropped their price target on shares of TC Biopharm from $112.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, December 6th.

TC Biopharm Stock Performance

The firm has a 50 day simple moving average of $2.69 and a two-hundred day simple moving average of $23.39.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.